François Ghiringhelli

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies

  OncoImmunology · 2026-06-20

• Table 1_An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy.docx

  Figshare · 2026-06-16

• Table 2_An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy.docx

  Figshare · 2026-06-16

• Image 2_An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy.tiff

  Figshare · 2026-06-16

• Image 1_An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy.tiff

  Figshare · 2026-06-16

• An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy

  Frontiers in Oncology · 2026-06-16

• Supplementary Table S1 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

  2026-06-15

• Supplementary Figure S4 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

  2026-06-15

• Supplementary Figure S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

  2026-06-15

• Data from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

  2026-06-15

• Supplementary Table S2 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

  2026-06-15

• Supplementary Figure S5 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

  2026-06-15

• Supplementary Figure S1 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

  2026-06-15

• Supplementary Table S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

  2026-06-15

• Supplementary Figure S2 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

  2026-06-15

• The mannosyltransferase DPM1 regulates the activity of ER-stress sensor IRE1 in colorectal cancer

  Nature Communications · 2026-06-03

• Historical Geography vs Sacred Geography

  Zeitschrift für Ägyptische Sprache und Altertumskunde · 2026-06-02

• Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective

  Cancer Treatment Reviews · 2026-06-01

• IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy

  Journal for ImmunoTherapy of Cancer · 2026-06-01

• Phase IIb randomized trial of FOLFIRINOX plus ibrilatazar (ABTL0812) versus placebo as first-line treatment in metastatic pancreatic cancer: An analysis from the PanC-ASAP study.

  Journal of Clinical Oncology · 2026-05-27